Assembly Biosciences (NASDAQ:ASMB) Rating Increased to Hold at StockNews.com

Assembly Biosciences (NASDAQ:ASMB) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Friday.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Assembly Biosciences in a research note on Monday, April 1st.

Assembly Biosciences Trading Up 1.0 %

Shares of NASDAQ:ASMB opened at $13.77 on Friday. The company has a market capitalization of $75.46 million, a price-to-earnings ratio of -0.81 and a beta of 0.57. Assembly Biosciences has a 12 month low of $7.69 and a 12 month high of $20.04. The firm’s 50-day moving average is $12.45 and its 200 day moving average is $10.67.

Insider Transactions at Assembly Biosciences

In related news, major shareholder Alexander Schornstein purchased 24,999 shares of the business’s stock in a transaction dated Wednesday, January 17th. The shares were purchased at an average cost of $9.36 per share, for a total transaction of $233,990.64. Following the completion of the acquisition, the insider now owns 655,357 shares in the company, valued at approximately $6,134,141.52. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders sold 2,066 shares of company stock worth $26,924. 4.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Assembly Biosciences

Several institutional investors have recently made changes to their positions in the company. Jane Street Group LLC bought a new position in Assembly Biosciences during the 1st quarter worth about $27,000. JPMorgan Chase & Co. boosted its stake in shares of Assembly Biosciences by 15,633.0% during the first quarter. JPMorgan Chase & Co. now owns 14,789 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 14,695 shares in the last quarter. Prudential Financial Inc. purchased a new position in Assembly Biosciences during the second quarter valued at approximately $36,000. Tower Research Capital LLC TRC raised its stake in Assembly Biosciences by 110.2% in the third quarter. Tower Research Capital LLC TRC now owns 17,150 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 8,992 shares in the last quarter. Finally, UBS Group AG lifted its holdings in Assembly Biosciences by 110.0% during the fourth quarter. UBS Group AG now owns 24,007 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 12,576 shares during the period. Hedge funds and other institutional investors own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study.